E2814

← Pipeline

E2814

Eisai · Alzheimer's disease
Mid-stage active active, not recruiting CT.gov grounded

A serious tau program that matters because the Alzheimer's field still needs credible combination therapy attempts.

Open Alzheimer's disease hub Filter main pipeline

Program overview

Mechanism
anti-MTBR tau antibody
Modality
monoclonal antibody
Phase
Mid-stage
Status
active
Recruitment
active, not recruiting
Confidence
medium
Watch priority
2
Last verified
20 Apr 2026

Sponsor and trial identifiers

Sponsor
Eisai
Trial IDs
NCT06602258, NCT04971733
ClinicalTrials.gov exact matches: NCT06602258, NCT04971733

Regions and recruitment

Active in 3 regions
United States Japan United Kingdom

Indication tags

Alzheimer's tau

Milestones and catalysts

Last milestone
Tau-directed combination work alongside lecanemab makes this one of the more strategically relevant next-wave Alzheimer's programs.
Next expected catalyst
Whether the tau-plus-amyloid combination thesis produces a clearer signal than monotherapy tracks.

Related pages

Disease hub Alzheimer's disease hub Disease-specific views with programs, mechanisms, and related context.
Research Research agenda Research notes and background around Alzheimer's disease.
Key Targets Key targets The mechanisms and intervention levers behind these programs.
Discover Discover Explainers and visual introductions to the science behind neurodegeneration.
Join Get involved Contribute research, writing, design, engineering, or review.

Related programs

Each card explains why it is here so you can read the overlap at a glance.

Priority 1
Approved / Late-stage active active, not recruiting

Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.

Shown because it shares same disease bench and same modality with E2814.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Further rollout, label evolution, and follow-up data.
Last verified
20 Apr 2026

Lecanemab

Eisai / Biogen · Alzheimer's disease
Priority 1
Approved / Late-stage active active, not recruiting

Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.

Shown because it shares same disease bench and same modality with E2814.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Additional post-approval data and uptake signals.
Last verified
20 Apr 2026
Priority 2
Mid / Late-stage active active, not recruiting

Follow-on anti-amyloid program that could matter for the next wave of Alzheimer's competition.

Shown because it shares same disease bench and same modality with E2814.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Recruitment updates and larger efficacy or safety read-throughs.
Last verified
20 Apr 2026
Priority 3
Mid-stage completed completed

Tau-directed antibody program that matters because Alzheimer's cannot stay a one-mechanism pipeline forever.

Shown because it shares same disease bench and same modality with E2814.
Mechanism
anti-tau antibody
Modality
monoclonal antibody
Next catalyst
Whether tau-antibody follow-through survives the broader amyloid-dominated landscape.
Last verified
20 Apr 2026

Recent program changes

Source links

ClinicalTrials.gov NCT06602258 ClinicalTrials.gov NCT04971733 ClinicalTrials.gov search Eisai pipeline
Scroll to Top